Clinical guideline highlights for the hospitalist: Management of immune‐related adverse events in patients treated with immune checkpoint inhibitor therapy-Reference-Cited by-同舟云学术

Clinical guideline highlights for the hospitalist: Management of immune‐related adverse events in patients treated with immune checkpoint inhibitor therapy

Published:2023-04-11 Issue:11 Volume:18 Page:1013-1016
ISSN:1553-5592
Container-title:Journal of Hospital Medicine
language:en
Short-container-title:Journal of Hospital Medicine

Author:

Chitnis Saurabh D.¹^ORCID,Mortazavi Amir¹

Affiliation:

1. Division of Medical Oncology, Department of Internal Medicine The Ohio State University Comprehensive Cancer Center Columbus Ohio USA

Abstract

GUIDELINE TITLE: Management of Immune‐Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy: ASCO Guideline UpdateRELEASE DATE: November 1, 2021PRIOR VERSION(S): February 14, 2018DEVELOPER: American Society of Clinical OncologyFUNDING SOURCE: American Society of Clinical OncologyTARGET POPULATION: Adult patients with cancer receiving treatment with immune checkpoint blockade inhibitors alone

Publisher

Wiley

Subject

Assessment and Diagnosis,Care Planning,Health Policy,Fundamentals and skills,General Medicine,Leadership and Management

Reference8 articles.

1. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs

2. Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance

4. Retrospective analysis of hospital admissions due to immune checkpoint inhibitor‐induced immune‐related adverse events (irAE)

5. Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sintilimab-induced severe erosive hemorrhagic gastritis and pyloric obstruction: a case report and literature review;Immunotherapy;2024-03-26

2. Research Advances of Immune Checkpoint Inhibitors Related Endocrine Adverse Events;Advances in Clinical Medicine;2024